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Abstract
MicroRNAs (miRNAs) are small non-coding RNAs that regulate various biological processes. Cell-free miRNAs measured in
blood plasma have emerged as specific and sensitive markers of physiological processes and disease. In this study, we
investigated whether circulating miRNAs can serve as biomarkers for the detection of autologous blood transfusion, a major
doping technique that is still undetectable. Plasma miRNA levels were analyzed using high-throughput quantitative real-
time PCR. Plasma samples were obtained before and at several time points after autologous blood transfusion (blood bag
storage time 42 days) in 10 healthy subjects and 10 controls without transfusion. Other serum markers of erythropoiesis
were determined in the same samples. Our results revealed a distinct change in the pattern of circulating miRNAs. Ten
miRNAs were upregulated in transfusion samples compared with control samples. Among these, miR-30b, miR-30c, and
miR-26b increased significantly and showed a 3.9-, 4.0-, and 3.0-fold change, respectively. The origin of these miRNAs was
related to pulmonary and liver tissues. Erythropoietin (EPO) concentration decreased after blood reinfusion. A combination
of miRNAs and EPO measurement in a mathematical model enhanced the efficiency of autologous transfusion detection
through miRNA analysis. Therefore, our results lay the foundation for the development of miRNAs as novel blood-based
biomarkers to detect autologous transfusion.
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Introduction
Autologous blood transfusions are prohibited in sports accord-
ing to the World Anti-Doping Agency (WADA) [1]. There is, at
present, no direct detection method, and the technique remains a
significant problem in all endurance sport disciplines. A method
that has provided acceptable sensitivity with low specificity is the
detection of plasticizers and their metabolites, emanating during
storage from the blood bags, which can be measured in urine [2].
Nevertheless, athletes might shift to use plasticizer-free blood bags
to avoid this form of detection. The most promising approach to
detect autologous transfusion is the Athlete Biological Passport
(ABP), which is an indirect detection method, i.e., not the
forbidden substance or method itself is detected, but rather its
effects on certain biomarkers.
The ABP consists of longitudinal monitoring of different
biomarkers to identify patterns suspicious of doping [3], [4]. The
hematological module of the ABP uses blood markers to identify
any modification of erythropoiesis [4]. In the same context,
methods based on proteins as indirect markers for the detection of
exogenous recombinant human erythropoietin (EPO) abuse have
been described [5], [6]. In the future, new markers from
proteomics, metabolomics, and genomics might therefore be
integrated into the ABP to further enhance the detection of
autologous blood transfusion.
MicroRNAs (miRNAs) are small regulatory, non-coding RNAs
[7]. miRNAs primarily affect the stability of messenger RNA and/
or the initiation and progression of protein synthesis, but broader
regulatory roles have also been suggested [8], [9]. Recently, a
number of miRNAs were found outside of cells. These ‘‘circulating
miRNAs’’ are abundant in body fluids such as urine, saliva, and
plasma [10], [11] and were linked to different specific pathophys-
iological conditions. Examples of such conditions include the
association of plasma miR-122 with drug-induced liver injury [12],
[13], and the identification of miR-144 as a promising biomarker
to detect erythropoiesis-stimulating agents in anti-doping [14].
Compared to protein-based biomarkers, miRNA offers several
advantages: miRNAs are very stable in various body fluids,
expression of some miRNAs is restricted to specific tissues, and
miRNA levels can be easily measured by common laboratory
methods, including assorted signal amplification strategies [15].
Therefore, the purpose of this study was to investigate whether
circulating miRNAs can be used as biomarkers to detect
autologous blood transfusion in an anti-doping context. Other
indirect parameters commonly used for the indirect detection of
blood transfusion, hemoglobin concentration (Hb) and EPO
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concentration, were measured and compared with circulating
miRNA data.
Materials and Methods
Subjects
In total, 20 healthy male subjects were recruited for the study.
One group (Intervention, N= 10) underwent blood collection and
autologous reinfusion 42 days later, and the remaining subjects
served as a control group (Control, N= 10). The baseline
characteristics of the study participants are outlined in Table 1.
Plasma and urine samples were obtained the day before (D-1) and
at several time points (3 h, 6 h (D0), D+1, D+3, D+7, and D+10)
after autologous blood transfusion. Control samples were taken
similarly, except with no samples collected at 3 h and 6 h on D0).
The timeline of the study is illustrated in Figure 1.
Anti-doping regulations were not violated since none of the
subjects in the Intervention group was a license-holder in any
sports discipline. The ethics committee at the University of
Freiburg approved the study procedures (Amendment to Approval
No. 177/06), and written informed consent was obtained from all
subjects before participation.
Blood Donation and Reinfusion
One full bag of blood (approximately 500 mL) was removed
from each volunteer using international standard methods of
transfusion medicine. The volume of packed red blood cells
(RBCs) in the blood bag after processing and isolation was
approximately 280 mL, with a hematocrit of 53–60%. During the
preparation of packed RBCs, leukocytes were removed from
whole blood by centrifugation and application of leukocyte filters.
PAGGS-M was used as the storage solution. The RBCs were
stored at 4uC in temperature-regulated refrigerators until reinfu-
sion.
Hematology and Clinical Chemistry
Venous blood samples from an antecubital vein were obtained
following standard procedures. Blood was drawn into a 9-mL
serum tube and a 2.7-mL ethylenediaminetetraacetate (EDTA)
tube (Sarstedt S-Monovette, Sarstedt AG, Nu¨rnbrecht, Germany).
EDTA samples were analyzed for blood parameters using a fully
automated hematology analyzer (Sysmex XE-2100, Sysmex,
Norderstedt, Germany). Plasma from EDTA samples was
centrifuged 10 min at 4000 rpm, collected, aliquoted, and frozen
at 220uC until analysis. Serum samples were used for different
analyses, which were performed in batch for all samples to reduce
analytical variability. To test hemolysis in plasma, hemoglobin
concentration was quantified using a plasma/low Hb photometer
(HemoCueH, HemoCue AG, Wetzikon, Switzerland).
C-reactive protein (CRP), lactate dehydrogenase (LDH), EPO,
and ferritin were measured in plasma using Immulite technology
(Siemens AG, Erlangen, Germany) [16]. Human serum amyloid A
(SAA) and surfactant protein D were measured in plasma using
ELISA technology (Invitrogen, Carlsbad, USA and Biovendor,
Brno, Czech Republic) in the Intervention group.
MicroRNAs Quantitative Real-time PCR (qRT-PCR)
Total RNA, including miRNAs, was isolated from 200 mL
plasma using the miRNAeasy kit (Qiagen) as described elsewhere
[15], [14]. Total RNA samples of liver, heart, lungs, spleen,
thymus, kidney, skeletal muscle, adipose tissue, and brain were
derived from the FirstChoiceH Human Total RNA Survey Panel
(Invitrogen, Carlsbad, USA). Total RNA of whole blood was
derived from a pool of 10 blood samples (plasma and cells).
For miRNA profiling, 4 mL of eluted RNA was used in a 20-mL
reverse transcription (RT) reaction. UniSp6 Spike-in miRNA was
added to the RT reaction mix. The resulting cDNA was diluted
110 times and profiled for the relative abundance of 369 miRNAs
using miRNA Ready-to-Use PCR, Human panel I, V1.M
quantitative real-time PCR (qRT-PCR) arrays (Exiqon), as
Figure 1. Study design. Samples were taken at different time points after blood reinfusion. For the control group, no samples were collected at 3
(3 h) and 6 hours (6 h).
doi:10.1371/journal.pone.0066309.g001
Table 1. Baseline characteristics of groups.
Group Intervention (n =10) Control (n = 10)
Age, y (mean ± SD) 2562 2562
Weight, kg (mean ± SD) 7266.2 71.366.6
Height, m (mean ± SD) 17965 18065
Hb, g/dL (mean± SD) 15.765.0 15.261.2
Hb : hemoglobin
doi:10.1371/journal.pone.0066309.t001
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described in the manufacturer’s instructions. PCR amplification
was performed using a Roche LightCycler 480 real-time PCR
system. Raw data analyses were performed with LightCycler 480
software (release 1.5.0). Following a procedure similar to that
described by Pritchard et al. [17], the spike-in UniSp3 (represent-
ed in triplicate on the panel) and UniSp6 were used to normalize
the array data. The average Cq (quantification cycle; standard
name for Ct or Cp value) values of the 4 spike-ins (avgSpikes) were
calculated for each array. The array with the lowest avgSpikes
value was used as the baseline array. For the other arrays, the Cq
values were shifted by the difference between the array avgSpikes
and the avgSpikes of the baseline array. Cq values greater than or
equal to 36 were considered beyond the limit of detection. For
subsequent analyses, 242 miRNAs (of 382 total) with at least 4 Cq
values (out of 18 samples) lower than 36 were retained.
Differentially expressed miRNAs were identified using the R
package LIMMA [17], using a linear model with the difference
between D21 and D+1 and the subject as factors. The false
discovery rate (FDR) was computed using the Benjamini &
Hochberg method [18]. The 95% confidence interval for the fold
changes between the two time points was computed using the R
function ‘‘t.test.’’
For individual qPCR, RT and qPCR procedures were
performed as described above. However, 20 mL of RT reaction
was diluted 206 instead of 1106, and 4 mL of the diluted cDNA
was used in 10-mL PCR amplification reactions. A non-template
control was added to verify the specificity of the RT-qPCR. PCR
efficiency and the dynamic range of quantification were similar for
every tested sample. All sequences of primers are available on the
Exiqon web site (http://www.exiqon.com/ls/_layouts).
To better understand the time course of changes in circulating
miRNAs after blood reinfusion, individual qPCR assays on miR-
26b, miR-30b, and miR-30c were performed. These miRNAs
were selected due to their low Cq, high significance, and 3-fold
change. Since miR-486 was not affected by blood reinfusion
(Table 2), it was used as an endogenous internal control together
with a spiked artificial miRNA (UniSP6). Normalization was
performed using LightCycler 480 software (release 1.5.0) by
annotating miR-486 and UniSp6 as ‘‘reference.’’
Combining Analyses
The formula (miR-30b/miR-Ctls)*(1/EPO) was used to test
combination of analyses. Quantified cycles (Cq) from miR-30b
were divided by miR-486-5p and UniSp6 Cq with LightCycler
480 software, release 1.5.0. The circulating miR-30b value was
chosen due to its high concentration in plasma, fold change, and
specificity. Because of the decrease of EPO concentration after
autologous transfusion, the value 1/EPO was chosen to amplify
miR-30b/miR-Ctls changes.
Statistics
Statistical analysis was performed using two-tailed Student’s t-
test. Quantitative data are expressed as mean 6 SEM versus D-1,
unless otherwise specified. P values less than 0.05 were considered
to indicate statistical significance. Statistical analyses were
performed using Stata software (StataIC 12, StataCorp). ANOVA
was performed in R (function aov) using the sample collection time
and subjects as factors. Post-hoc pairwise comparisons were
performed with the R function TukeyHSD (Tukey’s Honestly
Significant Differences). Comparisons with a P value ,0.05 after
adjustment for multiple comparisons were considered significant.
Table 2. Most affected miRNAs by blood re-infusion.
miRNAs Fold-Change(FC) FC.low FC.high Average Cq P.Value FDR
hsa-let-7d 3.16 1.48 6.76 30.01 0.0028 0.105
hsa-miR-26b 3.03 1.42 6.48 28.67 0.0036 0.105
hsa-miR-30c 3.01 1.76 5.16 29.55 0.0005 0.105
hsa-miR-30b 2.98 1.48 6.00 27.42 0.0025 0.105
hsa-miR-142-3p 2.83 1.38 5.79 25.96 0.0039 0.105
hsa-miR-103 2.62 1.47 4.67 25.56 0.0021 0.105
hsa-let-7g 2.49 1.36 4.56 27.19 0.0039 0.105
hsa-miR-26a 2.40 1.33 4.34 27.46 0.0043 0.105
hsa-let-7b 2.15 1.33 3.48 27.75 0.0040 0.105
hsa-miR-339-5p 2.14 1.37 3.34 31.39 0.0030 0.105
hsa-miR-486-5p 1.01 21.59 1.62 27.84 0.9623 0.994
UniSp6 1.02 21.07 1.10 18.18 0.9076 0.956
doi:10.1371/journal.pone.0066309.t002
Table 3. miRNAs among 10 tested organs.
miRNAs Predominately expressed tissues
miR-let-7d Heart, Lung
miR-26b Lung, Spleen
miR-30c Heart, Lung
miR-30b Heart, Lung
miR-142-3p Thymus,Spleen
miR-103 Brain, Lung
miR-let-7g Lung, Heart
miR-26a Lung, Skeletal muscle
miR-let-7b Lung, brain
miR-339-5p Kidney, Lung
miR-486-5p Whole blood, Skeletal muscle
doi:10.1371/journal.pone.0066309.t003
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Figure 2. Circulating miRNA levels after autologous blood in the Intervention and Control groups. Levels of miR-30b, miR-30c and miR-
26b in plasma samples collected from healthy volunteers after blood reinfusion (Intervention) or in the control group. The collection time points are
indicated on the x-axis. Data were normalized to endogenous miR-486-5p and spike-in UniSp6 controls (Ctls). The values of miRNAs are the average
of 10 independent samples from each time point. ***P#0.001, statistical analyses are presented in Table 4.
doi:10.1371/journal.pone.0066309.g002
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Results
Screening of circulating miRNAs as autologous transfusion
biomarkers was performed with qRT-PCR 1 day before and at
various times after reinfusion (see Figure 1, Table S1). Data were
analyzed using a linear model allowing pairing of the values by
subjects (Table S2). The most significant miRNAs (FDR=0.105)
were selected for further investigations (Table 2). All these
miRNAs demonstrated a fold-change increase larger than 2, and
members of the same family were present, such as miR-let-7, miR-
30, and miR-26 miRNAs. By contrast, no significant decrease of
circulating miRNAs was observed after blood reinfusion (Table
S2). The highest significant increases observed in plasma after
blood reinfusion was in miR-let-7d, miR-26b, miR-30b, and miR-
30c, with an average of 3-fold increase.
As the changes in miRNA levels could be due to different
physiological responses related to autologous transfusion, two
tissues with the highest expression of miRNAs were selected. In 9
of the 10 selected miRNAs (90%), the lungs were the tissue with
most miRNA affected by autologous transfusion (Table 3).
Additionally, an increase of surfactant protein D, a lung-specific
protein, was observed (Figure S1).
Regarding the timeline, the reinfusion induced miR-30b, miR-
30c, and miR-26b with a peak of induction one day (D+1) after
blood transfusion (Figure 2, Intervention). ANOVA analyses
demonstrated that the induction of miR-30b, miR-30c, and
miR-26 was highly statistically significant (Table 4). Circulating
miR-30b and miR-30c were already induced significantly at 3
hours after reinfusion. The control group showed no significant
changes in any of the measured miRNAs (Figure 2, Control and
Table 4).
Three of 10 Intervention subjects displayed an increase of the
liver-specific miR-122 [19] (Figure 3). Interestingly, SAA [20], a
hepatic acute-phase reactant protein, was also elevated in the same
subjects after reinfusion (Figure 3). No significant change was
observed in the biochemical markers for leukocytes, CRP and
LDH, after blood cell transfusion (Table 5).
The effect of autologous blood transfusion on traditional blood
parameters was then compared to the change of circulating
miRNAs. Erythrocyte count and hemoglobin concentration were
increased 1 day after blood reinfusion (Table 5). No significant
change was observed in the control group (Table 5). No significant
change was observed in reticulocyte percentage after blood
reinfusion (Table 5). Transfusion was associated with a significant,
long-term decrease in EPO up to 10 days after blood reinfusion
and an increase in ferritin (Table 5). No significant change was
observed in the control group for these variables (Table 5).
Since circulating miRNA and EPO level in blood were both
significantly influenced by autologous transfusion, the combination
of the different variables was tested to increase the sensitivity of this
biomarker approach. The amount of circulating miR-30b was
divided by the EPO concentration. Three individual subjects are
displayed as an example (Figure S2a, b and c). By dividing miRNA
data by EPO concentration, the fold change compared to D-1 was
increased by ,50% compared to the values of circulating miR-
30b alone. In addition, the statistical significance of the fold
change 3 days after transfusion was increased, from P=0.04 to
P=0.01 (Figure 4).
Discussion
The key finding of our study is that the transfusion of autologous
blood triggers an increase of selected circulating miRNAs in
plasma compared to a non-transfused control group. These results
suggest that circulating miRNAs may serve as biomarkers to detect
autologous transfusion, especially when the change of miRNAs is
combined with the long-term decrease of EPO after autologous
transfusion in a mathematical model.
Screening for a potential ‘‘circulating miRNA signature’’ after
blood reinfusion showed that 10 distinct miRNAs were candidates
to serve as efficient biomarkers for the detection of autologous
blood transfusion. The changes of miRNA levels could be due to
different physiological responses to autologous transfusion. All
plasma miRNAs have a tissue or cellular origin [21]. Thus,
measurement of a specific circulating miRNA in different tissues is
a strategy to confirm its origin [22].
Many circulating miRNAs found in plasma are highly expressed
in various peripheral blood cells [17]. Thus, changes in miR-30b,
miR-30c, and miR-26b after transfusion could be explained by an
increase of cell lysis during storage leading to a higher level of
plasma miRNAs after reinfusion. However, miRNAs such as miR-
30b and miR-30c are mainly expressed in white blood cells [17].
As leukocytes were removed during the preparation of whole
blood, the chance that miR-30b, miR-30c, and miR-26b are
transfused with the packed RBC is limited.
Furthermore, as miR-486-5p is highly expressed in RBC [17]
but does not increase after blood reinfusion, the release of
miRNAs from destructed RBCs seems unlikely. In addition, our
results were derived from whole blood samples at time points
within hours and days after transfusion, when an adequate mixture
of RBCs coming from the stored blood bag (280 mL packed
RBCs, approximately 5–7% of total blood volume) and natural
RBCs can be expected. Thus, even if hemolysis had occurred in
the stored blood bag with subsequent reinfusion of released
miRNAs, then their representation in whole blood would be low.
In light of these arguments, it seems unlikely that hemolysis of
stored blood is the main explanation for the increase of miR-30b,
miR-30c, and miR-26b after blood reinfusion.
Tissue measurement demonstrated that most of the screened
miRNAs were predominantly expressed in the lungs. Significant
Table 4. ANOVA analyses of individual qPCR.
Group miRNA F value P value Significant post-hoc pairwise comparisons
Intervention 26b 6.642752 2.80E-05 D1-D-1, D10-D1, D3-D1, D7-D1
Intervention 30b 7.946132 3.93E-06 D1-D-1, D10-3h, D10-6h, D10-D1, D3-D1, D7-D1
Intervention 30c 5.594842 0.000149 D1-D-1, D10-3h, D10-D1, D3-D1, D7-D1
Control 26b 1.077540 0.381995
Control 30b 0.060522 0.992925
Control 30c 1.248051 0.308249
doi:10.1371/journal.pone.0066309.t004
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Figure 3. Liver-specific circulating miRNA miR-122 and level of serum amyloid A (SAA) after transfusion in three volunteers. The
collection time points are indicated on the x-axis. Data were normalized to endogenous miR-486-5p and spike-in UniSp6 controls (Ctls). The relative
changes of different miRNA levels are compared with D-1. Values represent the mean of three independent experiments 6 SD. *P#0.05 and
**P#0.01 versus D-1.
doi:10.1371/journal.pone.0066309.g003
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increase of surfactant protein D, a lung-specific blood protein [23],
confirmed that pulmonary physiology is involved in the changes
triggered by autologous blood transfusion (Figure S1). In studies
with a murine transfusion model, prolonged storage of RBCs
before transfusion into endotoxemic mice caused increases in lung
chemokines [24]. In addition, so-called transfusion-related acute
lung injury (TRALI) is a serious blood transfusion complication
characterized by the acute onset of non-cardiogenic pulmonary
edema following the transfusion of blood products [25]. Altogeth-
er, these observations suggest that autologous transfusion impacts
pulmonary physiology, now mirrored by miRNA measurements.
The mechanism behind the secretion of miRNAs from the lungs
into the bloodstream remains unclear. One proposed hypothesis is
that all types of circulating miRNA in the biological fluids are
merely byproducts of cellular activity [26], [27]. Indeed, autolo-
gous transfusion could trigger secretion of multiple lung-specific
Table 5. Hematologic variables before and during 10 days after transfusion.
Intervention D–1 D+1 D+3 D+7 D+10
Reti (%) 0.7560.03 0.8060.04 0.8060.03 0.7260.04 0.7260.04
LDH (UI/L) 158.763.6 170.765.7 167.462.8 183.567.0 171.466.8
Leuk (103/mL) 5.360.2 6.160.5 5.660.2 6.460.3 6.260.3
CRP (mg/dL) 0.860.3 0.560.1 0.360.1 0.560.2 0.360.1
Ery (106/mL) 5.0860.05 5.3260.06* 5.2160.07 5.2260.06 5.2160.06
Hb (g/dL) 15.2460.15 16.0260.14* 15.7160.13* 15.7560.13* 15.760.13*
EPO (UI/L) 13.760.85 10.0760.80 9.3160.44* 9.6760.86* 8.0160.56**
Ferritin (ng/mL) 54.0967.04 103.57613.04* 87.2469.4** 75.6467.92** 82.4368.17**
Control D-1 D+1 D+3 D+7 D+10
Reti (%) 0.8560.05 0.8460.05 0.9360.05 0.960.05 0.9160.04
LDH (UI/L) 172.765.2 158.566.0 147.563.6 16769.8 154.766.4
Leuk (103/mL) 7.460.4 6.760.5 5.960.3 6.960.4 6.660.4
CRP (mg/dL) 0.860.2 0.660.1 0.760.1 1.260.3 1.260.3
Ery (106/mL) 4.9660.05 4.8860.04 4.960.05 4.8560.05 4.8260.06
Hb (g/dL) 15.2260.23 15.0160.14 14.9560.22 14.8760.24 14.6660.24
EPO (UI/L) 11.3561.57 13.9462.22 12.4161.77 11.662.09 14.3262.25
Ferritin (ng/mL) 71.368.64 77.669.57 71.6569.49 73.1969.44 70.5769.47
Abbreviations : percentage of reticulocytes (Reti), lactate deshydrogenase (LDH), leukocytes (Leuk), C-reactive protein (CRP), erythrocytes (Ery), hemoglobin (Hb),
erythropoietin (EPO) * and ** = significant difference (p#0.05 and p#0.01, resp.) from D-1 (one day before blood re-infusion).
doi:10.1371/journal.pone.0066309.t005
Figure 4. Combination of EPO and circulating miRNA. The levels of miR-30b and 1/EPO were compared with miR-30b alone. The collection
time points are indicated on the x-axis. The relative changes of different miRNA levels are compared with D-1 (one day before transfusion). Data were
normalized to endogenous miR-486-5p and spike-in UniSp6 controls (Ctls) The values for miRNAs are the average of 10 independent samples from
each time point. Values are presented as mean 6 SEM. *P#0.05 and **P#0.01 versus D-1.
doi:10.1371/journal.pone.0066309.g004
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molecules such as proteins and miRNAs with poor selectivity. Our
results concerning the secretion of human surfactant protein D
and circulating miRNAs after blood reinfusion might support this
‘‘byproduct hypothesis.’’
Reproducibility studies regarding miRNA analyses have
emphasized the importance of choosing an endogenous control
to counteract the physiological variance in miRNA levels between
individuals. In our study, miR-486-5p and a spiked artificial
UniSp6 miRNA were used as control miRNAs. No effect due to
transfusion was observed with miR-486-5p (Table 1). Moreover, it
was found at a high level in plasma (27.9 Ct) and had already
proven suitable as an endogenous control in prior studies [28].
This miRNA was therefore chosen as an endogenous control to
normalize the data.
The three best candidates selected for longitudinal assessment
with individual normalized RT-qPCR over the study period were
miR-30b, miR-26b, and miR-30c. These miRNAs demonstrated
the highest plasma concentration, fold change, and statistical
significance. In the same context, Let-7d was ruled out of the
selection due to its low plasma concentration and specificity.
Measurement over time revealed a peak increase at 1 day after
blood reinfusion for miR-30b. A 4-fold change was observed for
miR-30b and miR-30c, and a 3-fold change for miR-26b. The
magnitude of the changes was unexpected considering the small
physiological effect of autologous blood transfusion on peripheral
blood markers. Moreover, the increase of miR-30b was still
detectable after 3 days. These results demonstrated that a number
of circulating miRNAs are influenced by reinfusion of stored
blood.
Elevated hepatic miR-122 was correlated with the increase of
SAA. Thus, genomic and protein analyses suggest that autologous
transfusion could trigger a hepatic reaction in certain volunteers.
In other studies, circulating miR-122 was demonstrated to increase
after liver damage [12], [13]. Altogether, our data suggest that
liver-secreted compounds may be interesting biomarkers to detect
autologous blood transfusion when monitored longitudinally. In
addition, the link between liver reaction and autologous blood
transfusion could be useful in a clinical context.
Measurements of different blood parameters such as Hb were
included in calculation models to detect autologous transfusion [3],
[4], [29]. In our study, a significant increase of Hb was observed 1
day after blood reinfusion, and hemoglobin tended to remain
elevated up to 10 days. These results are consistent with several
previous reports [29], [30], [3], [4]. Interestingly, reticulocytes did
not show any significant change, in contrast to previous reports
[3], [4]. A similar result, however, was found in the study by
Ashenden [29]. No significant change in general circulating
inflammatory parameters such as leukocytes or CRP was observed
in our study, as observed by others [30].
Our results demonstrated that autologous blood transfusion had
a significant impact on EPO and ferritin concentration. Iron
metabolism is impacted by stored blood in humans and mice [30],
[31], [32]. In our study, the level of ferritin was elevated after
blood transfusion and thus could be used as a potential biomarker
to detect blood doping. Previously, serum ferritin was proposed as
a biomarker to detect EPO abuse [6]. Supplemental oral iron
intake is frequently used by athletes to prevent iron deficiency
[33], [34] and such supplementation could easily interfere with the
function of ferritin as a biomarker in the detection of doping,
thereby reducing the specificity of this marker. The longitudinal
measurement of EPO is a potentially effective method to unmask
recombinant human EPO abuse in athletes [5], [6]. EPO is a key
player in erythropoiesis. Therefore, the decrease of EPO
concentration after the autologous transfusion in our study was
expected.
Current use of the ABP emphasizes the advantages of using a
combination of different biomarkers to detect doping in sports.
From the perspective of our study, a combination of circulating
miRNAs and EPO measurement might have greater discrimina-
tive power to detect autologous blood transfusion (Figure 4) than
miRNAs alone. As both variables are measured in the same
matrix, a single plasma-EDTA sample would be sufficient to
perform the test. Such samples are already in use for the
determination of hemoglobin and the other markers included in
the ABP [4]; thus, no additional sample material would need to be
taken from the athlete. Altogether, these data demonstrate that the
combination of different biomarkers increases the efficiency of
autologous blood transfusion detection. In this context, future
studies should evaluate how a new marker consisting of miRNAs
and EPO could be incorporated into the adaptive model of the
ABP [35].
This study has several limitations. The influence of various
confounding parameters such as high-altitude training, physical
exercise, and the analytical robustness of the proposed biomarkers
remains to be explored. However, our control group showed no
significant inter-day variability for EPO or miR-30b. Nevertheless,
long-term longitudinal measurements of the proposed miRNAs in
elite athletes and controls are needed before our results can be
implemented in a real anti-doping context or the adaptive model
of the ABP.
In summary, our results revealed a distinct change in the pattern
of circulating miRNAs, a specific ‘‘signature’’ after autologous
blood transfusion. We observed that the origin of these miRNAs
was related to pulmonary and liver tissues. The detection window
of the observed changes was up to 3 days after blood transfusion.
In the same context, the long-term changes observed in EPO
might be combined with the aforementioned markers in a
mathematical model to enhance the efficiency of detecting
autologous blood transfusion. Therefore, our results may lay the
foundation for the development of a combination of hematologic
and genomic biomarkers as a novel blood-based strategy to detect
autologous blood transfusion, perhaps as part of the adaptive
model of the ABP.
Supporting Information
Figure S1 Levels of surfactant protein D after autolo-
gous blood transfusion. Level of surfactant protein D in
plasma samples collected from healthy volunteers after autologous
blood transfusion. The collection time points are indicated on x-
axis. The relative change of different miRNA levels are compared
with D-1. The values of miRNAs are the average of 10
independent samples from each time points, values are presented
as mean 6 SEM. *P#0.05 versus D-1.
(TIFF)
Figure S2 Individual measurement of miR-30b, EPO
and combined values. Three subjects (A, B, C) were measured
individually for normalized miR-30b, EPO concentration and the
combination of both entities.
(PDF)
Table S1 Cq of miRNAs at D-1 and D+1 for each subject
in intervention group.
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Table S2 Total affected miRNAs by blood re-infusion.
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